<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d728">
    <sentence id="DDI-DrugBank.d728.s0" text="No specific cytochrome P450-based drug interaction studies have been conducted. "/>
    <sentence id="DDI-DrugBank.d728.s1" text="No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. ">
        <entity id="DDI-DrugBank.d728.s1.e0" charOffset="48-55"
            type="brand" text="ELOXATIN"/>
        <entity id="DDI-DrugBank.d728.s1.e1" charOffset="72-75"
            type="drug" text="5-FU"/>
        <pair id="DDI-DrugBank.d728.s1.p0" e1="DDI-DrugBank.d728.s1.e0"
            e2="DDI-DrugBank.d728.s1.e1" ddi="false"/>
    </sentence>
    <sentence id="DDI-DrugBank.d728.s2" text="Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ">
        <entity id="DDI-DrugBank.d728.s2.e0" charOffset="13-16"
            type="drug" text="5-FU"/>
        <entity id="DDI-DrugBank.d728.s2.e1" charOffset="104-111"
            type="brand" text="ELOXATIN"/>
        <pair id="DDI-DrugBank.d728.s2.p0" e1="DDI-DrugBank.d728.s2.e0"
            e2="DDI-DrugBank.d728.s2.e1" ddi="true" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d728.s3" text="Since platinum containing species are eliminated primarily through the kidney, clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; "/>
    <sentence id="DDI-DrugBank.d728.s4" text="although, this has not been specifically studied."/>
</document>
